astria therapeutics glp-1 receptor agonist weight management diabetes treatments Market Size & Analysis, 2026-2033 GLP-1 Receptor Agonists as Treatments

Med Hypotheses

A stoppage period shorter than four half-lives has questionable benefits

Kelly MS, Scopelliti EM, Goodson KE, Cma L, Nguyen HX, Simon B

For patients with MASLD, this means mazdutide could serve double duty: treating obesity while simultaneously addressing the liver disease that often accompanies it

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE-/- and LDLr-/- Mice by a Mechanism That Includes Inflammatory Pathways

Disclosure The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s)